Routine genotyping of human papillomavirus samples in Denmark

Johnson, Thomas; Bryder, Karin; Corbet, Sylvie; Fomsgaard, Anders

doi:10.1034/j.1600-0463.2003.t01-1-1110204.x

Cited by 21 publications

(28 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies conducted in European countries, such as Germany, Denmark, and Belgium, on the distribution of HPV types describe type-specific frequencies that agree with our results, with HPV31 being the second most common type, with frequencies of 10.1%, 8.0%, and 7.3%, respectively (1,25,37). The next most common type in our population is HPV58, with a frequency of 6.6%, probably due to the high proportion of women from South America, in which this type is the most frequent after HPV16 (8).…”

Section: Discussionsupporting

confidence: 81%

Oncogenic Human Papillomavirus (HPV) Type Distribution and HPV Type 16 E6 Variants in Two Spanish Population Groups with Different Levels of HPV Infection Risk

et al. 2006

View full text Add to dashboard Cite

The aim of this study is to determine oncogenic human papillomavirus (HPV) types and HPV type 16 (HPV16) variant distribution in two Spanish population groups, commercial sex workers and imprisoned women (CSW/IPW) and the general population. A multicenter cross-sectional study of 1,889 women from five clinical settings in two Spanish cities was conducted from May to November 2004. Oncogenic HPV infection was tested by an Hybrid Capture II (HC2) test, and positive samples were genotyped by direct sequencing using three different primer sets in L1 (MY09/11 and GP5؉/GP6؉) and E6/E7. HPV16 variants were identified by sequencing the E6, E2, and L1 regions. Four hundred twenty-five samples were positive for the HC2 test, 31.5% from CSW/IPW and 10.7% from the general population. HPV16 was the most frequent type. Distinct profiles of oncogenic HPV type prevalence were observed across the two populations. In order of decreasing frequency, HPV types 16, 31, 58, 66, 56, and 18 were most frequent in CSW/IPW women, and types 16, 31, 52, 68, 51, and 53 were most frequent in the general population. We analyzed HPV16 intratype variants, and a large majority (78.7%) belonged to the European lineage. AA variants were detected in 16.0% of cases. African variants belonging to classes Af1 (4.0%) and Af2 (1.3%) were detected. Different HPV types and HPV16 intratype variants are involved in oncogenic HPV infections in our population. These results suggest that HPV type distribution differs in CSW/IPW women and in the general population, although further analysis is necessary.Different epidemiological studies reveal that human papillomavirus (HPV) prevalence depends largely on age and sexual practices and that it shows major differences across geographic areas. HPV prevalence has been described to be higher in Latin America and sub-Saharan Africa and lower in Asia and Europe (12,15,17,30,32,35,40,43). More than 100 types of HPV have been identified to date, of which at least 42 are associated with infections of the genital tract (42). Different genotype prevalence profiles have also been observed in different geographic areas (8). Vaccines directed against HPV type 16 (HPV16) and HPV18, present in approximately 70% of cervical cancers worldwide, are currently under evaluation and have shown impressive reductions of 90% in the incidence of HPV infection in the case of types 16 and 18 (16, 18, 22, 27, 45). The preliminary data suggest that bivalent HPV16 and HPV18 vaccine may also protect against HPV16-related types (31, 33, 35, 52, and 58) and HPV18-related types (39, 45, 59, 68, and 85) (G. Dubin, 22nd International Papillomavirus Conference and Clinical Workshop 2005, Oral Communication F-03, 2005). In order to design and evaluate the health impact of HPV infections and the potential benefits of the implementation of future vaccines, it is necessary to know the distribution of oncogenic HPV types in different geographic regions and in different populations (29).In Spain, which has one of the lowest rates of cervical cancer worldwid...

show abstract

Section: Discussionsupporting

confidence: 81%

Oncogenic Human Papillomavirus (HPV) Type Distribution and HPV Type 16 E6 Variants in Two Spanish Population Groups with Different Levels of HPV Infection Risk

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Since the absence of HPV infection means that the risk of cervical cancer is negligible, testing for HPV has now been incorporated into screening programs that previously relied only on cytology (6). HPV DNA analysis has shown encouraging results when used in conjunction with cytological analysis in primary screening for cervical cancer in women 30 years of age or older (5,23). As a result of large randomized clinical trials, testing for HPV DNA is now recommended for most women with equivocal findings on cervical cytological analysis (atypical squamous cells of undetermined significance, also called ASCUS) (1,28).…”

mentioning

confidence: 99%

Evaluation of Combined General Primer-Mediated PCR Sequencing and Type-Specific PCR Strategies for Determination of Human Papillomavirus Genotypes in Cervical Cell Specimens

Fontaine¹,

Mascaux

Weyn³

et al. 2007

J Clin Microbiol

View full text Add to dashboard Cite

A strategy combining human papillomavirus general primer (mainly the PGMY primers)-directed PCR sequencing and type-specific PCR is presented. DNA samples were first tested in general primer-mediated PCR. The amplified fragments of positive samples after ethidium bromide-stained DNA gel analysis were further sequenced, and corresponding DNA samples were further analyzed by PCR using type-specific primers for human papillomavirus ( It is now well accepted that all cervical carcinomas contain at least one of the "high-risk" types of human papillomavirus (HPV) DNA (41). Over 100 HPV genotypes have been isolated to date. Among these more than 40 have been shown to infect the genital tract, and 15 of them (genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) have been found to be associated with cervical cancer or high-grade cervical intraepithelial neoplasia and therefore classified as high-risk types (31). In contrast, some HPV genotypes (6,11,40,42,43, 44, 54, 61, 70, 72, 81, and CP6108) are classified as low-risk types (31). Three additional types were classified as probable high risk (26, 53, and 66) while the risk of those previously undetected remains undetermined (31). Differences in geographic distribution of HPV types have been reported to exist between countries (10).Multiple concurrent and sequential infections with different oncogenic types of HPV are common, usually transient, and disappear spontaneously without clinical lesion. Only persistent high-risk HPV infection induces higher risk for the development of a high-grade precancerous lesion or cervical cancer (14,41,43). Since the absence of HPV infection means that the risk of cervical cancer is negligible, testing for HPV has now been incorporated into screening programs that previously relied only on cytology (6). HPV DNA analysis has shown encouraging results when used in conjunction with cytological analysis in primary screening for cervical cancer in women 30 years of age or older (5, 23). As a result of large randomized clinical trials, testing for HPV DNA is now recommended for most women with equivocal findings on cervical cytological analysis (atypical squamous cells of undetermined significance, also called ASCUS) (1, 28). Furthermore, HPV DNA testing provides a unique advantage for early detection of treatment failure (3,9,33,42). Recently, encouraging results with prophylactic HPV vaccines have been reported. These vaccines are believed to be effective against four different HPV types, including the most frequently encountered type, HPV-16. This further emphasizes the need for HPV DNA testing, which will be useful to guide vaccination and to monitor the frequency and the severity of infection by unaffected HPV types (15,20,21).Highly sensitive HPV DNA tests have been developed that rely on molecular biology techniques. For example, the FDA approved the HPV detection kit of Digene/Hybrid Capture 2 (HC2) manufactured by DiGene (MD). Within this test, genotype-specific RNA probes are mixed in a highrisk or a low-risk...

show abstract

“…Furthermore, due to the limited number of probes represented by the system and potential cross-hybridizations, it harbours the risk of wrong classifications in a substantial fraction of cases. One study comparing sequencing with hybrid capture identified revealed that about 15% of HPV infections were not found, of which 50% represented HR types [27]. In this study, the hybrid capture technique was not applied.…”

Section: Discussionmentioning

confidence: 93%

Inter-laboratory validation of PCR-based HPV detection in pathology specimens

Petersen¹,

Schewe²,

Schlüns³

et al. 2007

Virchows Arch

View full text Add to dashboard Cite

The detection and typing of human papilloma virus (HPV) in pathology specimens is gaining increasingly in importance. In the context of the initiative for quality assurance in pathology (QuIP) of the German Society of Pathology and the Professional Association of German Pathologists, four panel laboratories with experience and expertise in polymerase chain reaction (PCR)-based HPV detection were selected to establish an inter-laboratory trial. In a first step, these laboratories performed an internal testing of their own methodologies, which comprised DNA sequencing, multiplex nested PCR and hybridization techniques. Material from 39 samples including paraffin sections and DNA preparations of tissues and plasmids were evaluated by each panel institute according to their own protocols. Despite the different methodologies, a high degree of inter-laboratory reliability was achieved. In this report, we summarise the results. Pretested specimens are available for the external trail and can be ordered from the steering institute via provitro GmbH Berlin ( http://www.provitro.de ). Supplementary data are online available at http://pathologie-ccm.charite.de (rubric "Forschung"), which includes a web-based photo gallery of HPV-associated lesions and their potential association with specific virus types. The initiative is intended to foster the quality assurance of molecular HPV analysis in pathology and its correlation with morphological changes.

show abstract

Routine genotyping of human papillomavirus samples in Denmark

Cited by 21 publications

References 30 publications

Oncogenic Human Papillomavirus (HPV) Type Distribution and HPV Type 16 E6 Variants in Two Spanish Population Groups with Different Levels of HPV Infection Risk

Oncogenic Human Papillomavirus (HPV) Type Distribution and HPV Type 16 E6 Variants in Two Spanish Population Groups with Different Levels of HPV Infection Risk

Evaluation of Combined General Primer-Mediated PCR Sequencing and Type-Specific PCR Strategies for Determination of Human Papillomavirus Genotypes in Cervical Cell Specimens

Inter-laboratory validation of PCR-based HPV detection in pathology specimens

Contact Info

Product

Resources

About